PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE quired to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known			
Application Number	09/703.753		
Filing Date	November 1, 2000		
	Robert E. Dudley		
	1617		
	S. Jiang		
Attorney Docket Number	01736349		

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*		Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
5 9K)	1	us-4496556	01/29/1985	Orentreich	
	2	us-4695465	09/22/1987	Kigasawa, et al.	
	3	us-4863970	09/05/1989	Patel, et al.	
	4	us-4946870		Partain, et al.	
	5	us-5053227	10/01/1991	Chiang, et al.	
	6	us-5059603	10/22/1991	Rubin	, .
	7	us-5152997	10/06/1992	Ebert, et al.	
	8	us-5256652		El-Rashidy	
	9	us-5324521		Gertner, et al.	
	10	us-5332577	07/26/1994	Gertner, et al.	
	11	us-5340586	08/23/1994	Pike, et al.	
	12	us-5346901		Bell, et al.	
	13	us-5362497	11/08/1994	Yamada, et al.	
	14	us-5413794	05/09/1995	Suzuki, et al.	
	15	us-5460820		Ebert, et al.	
	16	US-5550107		Labrie	
	_17	US- 5648350		De Lignieres	
	18	US- 5719197		Kanios, et al.	
	19	us-5723114	03/03/1998	Thornfeldt, et al.	
299	20	US-5744162		Okabe, et al.	

		FORE	IGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (tr known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
					<u>:</u>	
				·		
			:			
						Н

Examiner Date Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbol Total Indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

MAR 28 2002 SS

& TRADE

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1985 no persons are regard to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 21

Co	omplete if Known	
Application Number	09/703.753	
Filing Date	November 1, 2000	
First Named Inventor	Robert E. Dudley	
Art Unit	1617	
Examiner Name	S. Jiang	
Attorney Docket Number	01736349	

 . ,	U.S. PATENT DOCUMENTS					
Examiner Initials*		Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
591	21	us-5785991	07/28/1998	Burkoth, et al.		
	_22	US-5788983	08/04/1998	Chien. et al.	·	
	23	US-5855905	01/05/1999	Oettel, et al.		
	24	us-5877216	03/02/1999	Place, et al.		
	25	us-5932227	08/03/1999	Higo, et al.		
	26	us-5955455		Labrie		
41	27	us-6010716	01/04/2000	Saunal, et al.		
	28	us-6036977	03/14/2000	Drizen, et al.		
\perp	29	us-6037346	03/14/2000	Doherty, et al.		
	30	us-6075028		Graham		
	31	us-6077841	06/20/2000	Sui, et al.		
1	32	us-6087362	07/11/2000	El-Rashidy		
	33	us-6087368		Macor, et al.		
	34	us-6103765		Neal		
	35	us-6124461	09/26/2000	Shoemaker		
	36	us-6127363	10/03/2000	Doherty, et al.		
	37	us-6139873	10/31/2000	Hughes, Jr., et al.		
	38	us-6156753	12/05/2000	Doherty, et al.		
Jad	/39	us-6238284 B1	05/29/2001	Dittgen, et al.		
294	40	us-6248363 B1	06/19/2001	Patel, et al.		

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages				
	_	Country Code 3 -Number 4 -Kind Code 5 (#known)	MM-DD-YYYY	The second of th	or Relevant Figures Appear	ľ			
						L			
						⊬			
						⊢			
						T			
						L			
						L			
						L			

Examiner Signature	SAY	Date Considered	4/25/02
			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE quired to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 21

Complete if Known				
Application Number	09/703.753			
Filing Date	November 1, 2000			
	Robert E. Dudlev			
Art Unit	1617			
Examiner Name	S. Jiano			
Attorney Docket Number	01736349			

				U.S. PAT	ENT DOCUMENTS	
Examiner Initials*		Document Number Number - Kind Code ² (if kr	nown,	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
594)	41		B1	06/26/2001	Drizen, et al.	
7	42		<u>B1</u>	07/24/2001	Zhang, et al.	
	43		B1	07/31/2001	Chen, et al.	
	44	US-6277884	B1	08/21/2001	de Teiada	
	45		<u>B1</u>	09/25/2001	Patel, et al.	
	46		B1	09/25/2001	Place, et al.	
	47		B1	10/09/2001	Reed, et al.	
	48	US-6306841	B1	10/23/2001	Place, et al.	
	49	US-6323242	B1	11/27/2001	Mueller	
	50	US-6331543	B1	12/18/2001	Garvey, et al.	
	51	US-010018073	41	08/30/2001	Dittgen, et al.	
	52	US-010023261 /	41	09/20/2001	Ryoo, et al.	
	53	US-010033870 A	41	10/25/2001	Luo, et al.	
	54	US-010036483	41	11/01/2001	Luo, et al.	
	/ 55	US-010051166 A	41	12/13/2001	Luo, et al.	
599	56		41	12/13/2001	Place, et al.	
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS								
Examiner Cite	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.1	Country Code 3 - Number 4 - Kind Code 5 (# known)		Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T®		
59X	57	wo 92/15289 A1	09/17/1992	Mantelle				
10	58	WO 93/25168 ✓ A1	12/23/1993	Heiber, et al.				
	59	wo 94/21230 A1	09/29/1994	Elias, et al.				
	60	wo 94/28902 A1	12/22/1994	Ellis, et al.				
	61	WO 96/16644 A1	06/06/1996	Campbell, et al.				
	62	wo 96/16657 A1	06/06/1996	Cambell, et al.				
	63	wo 96/27372 A1	09/12/1996	Allen		Γ		
	64	wo 96/36339 A2	11/21/1996	Mantzoros		Г		
	65	wo 97/03985 A1	02/06/1997	Daugan, et al.				
990	66	wo 97/24148 Al	07/10/1997	Chen, et al.				

Examiner Date Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

MAR 2 8 2002 55

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE quired to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1995, no persons are equired to respond to a collection of info control number.

A TRADE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 21

Complete if Known				
Application Number	09/703.753			
Filing Date	November 1, 2000			
First Named Inventor	Robert E. Dudley			
Art Unit	1617			
Examiner Name	S. Jiang			
Attorney Docket Number	01736349			

			U.S. PATE	NT DOCUMENTS	
Examiner	Cita	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*		Number-Kind Code ² (if known)	1414 DD 10004	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-			
	Ţ <u> </u>	US-			
		US-			
		US-			
		US-			·
	Ī	US-			
		US-			
		US-			
		US-]		
		US-			
		US-			
		US-			
		US-			
	Π	US	•		
		US-			
		US-			
$\overline{}$	T	US-			

		FOR	EIGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (# Innown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
Say	67	wo 97/43989 A1	11/27/1997	Portman, et al.		
	68	WO 98/34621 A1	08/13/1998			
	69	wo 99/24041 A1	05/20/1999	Mak. et al.		
	70	wo 99/66870 A1		Fotinos		
	71	wo 00/45795 A2	08/10/2000	Lulla, et al.		
	72	wo 00/76522 A1	12/21/2000	Rosario-Jansen, et al.		
	73	wo 01/52823 A2	07/26/2001	Kanios		
	74	wo 01/76608 A1	10/18/2001	Lipp, et al.		
	75	EP 0196769 A2	10/08/1996	Chien, et al.		
540	76	EP 0483105 B2	04/29/1992	Cleary		

Examiner Signature Date Considered 4/25/67

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

¹ Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 to persons a valid OMB outrol number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 21

Complete if Known				
Application Number	09/703.753			
Filing Date	November 1, 2000			
First Named Inventor	Robert E. Dudley			
Art Unit	1617			
Examiner Name	S. Jiang			
Attorney Docket Number				

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*		Document Number Number-Kind Code ² (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US	· .		
		US ₂			
		∕us.			
		US-			
	·	US-			
		US-			

		FOR	EIGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7,
GUY	77	EP 0491076 A1	06/24/1992	Patel, et al.		Г
	78	EP 0513832 A1	11/19/1992	Рагав		Г
500	79	EP 0581587 A2	02/02/1994	Kobayashi, et al.		
4			ļ			┖
	- -		ļ			Ļ
						┝
			†		<u> </u>	⊬
			 			一
	•		1			t

Examiner Signature Date Considered Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

十

RECEIVED

Under the Paperwork Reduction Act of 18 control number.

PTO/SB/08B/(1001) 2002
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE quired to respond to a collection of information unless it contains a valid OMB 1000/2

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

O persons and TRADE

Complete if Known **Application Number** 09/703.753 Filing Date November 1, 2000 **First Named Inventor** Robert E. Dudley Group Art Unit 1617 **Examiner Name** S. Jiana Attorney Docket Number 01736349

(use as many sheets as necessary) of Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
A)	80	RINGHAM, ET AL., "Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel in Hypogonadal Men," Unimed Pharmaceuticals (October 31, 2000).	
	81	LONGSTRETH, ET AL., "Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment," Unimed Pharmaceuticals (October 31, 2000).	
·	82	KAUFMAN, "Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation," International Journal of Impotence Research," Vol. 12 (Supplement 3), p. S75 (B9) (September 2000).	
		JORDAN, "Allergy and Topical Irritation Associated With Transdermal Testosterone Administration: A Comparison of Scrotal and Nonscrotal Transdermal Systems," American Journal of Contact Dermatitis. Vol. 8 (No. 2). pp. 108-113 (June 1997).	
	84	GOUCHIE, ET AL., "The Relationship Between Testosterone Levels and Cognitive Ability Patterns," Psychoneuroendocrinology, Vol. 16 (No. 4), pp. 323-334 (1991).	
	85	DOBS, ET AL., "Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 10), pp. 3469-3478 (1999).	
	 86	PERSKY, ET AL., "Plasma Testosterone Level and Sexual Behavior of Couples," Archives of Sexual Behavior, Vol. 7 (No. 3), pp. 157-173 (May 1978).	
	87_	AHMED, ET AL., "Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism," Journal Of Clinical Endocrinology And Metabolism, Vol. 66 (No. 3), pp. 546-551 (March 1988).	
·	88	BALS-PRATSCH, ET AL., "Transdermal Testosterone Substitution Therapy for Male Hypogonadism," The Lancet, Vol. 2 (No. 8513), pp. 943-46 (October 25, 1986).	
		PLYMATE, ET AL., "Circadian Variation in Testosterone, Sex Hormone-Binding Globulin and Calculated Non-Sex Hormone-Binding Globulin Bound Testosterone in Healthy Young and Elderly Men," Journal of Andrology, Vol. 10 (No. 5), pp. 366-371 (September-October 1989).	
Sol		CUNNINGHAM, ET AL., "Testosterone Replacement with Transdermal Therapeutic Systems - Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels," JAMA, Vol. 261 (No. 17), pp. 2525-2530 (May 5, 1989).	

Examiner	5g0	Date 4/x/v
Signature		Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are require control number.

Application Number

First Named Inventor

Filing Date

Group Art Unit

November 1, 2000

Robert E. Dudley

1617

Approved for use through 10/31/2002 OMB 0651-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB 2002

		_	
;o	mplete If Known-CH CENTE	ם	1/20/0000
	09/703 753	1 1	TQJU/2000

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Examiner Name Jiana Attorney Docket Number of Sheet 01736349

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
<i>T</i>	91	TENOVER, ET AL., "Age-Related Alterations in the Circadian Rhythms of Pulsatile Luteinizing Hormone and Testosterone Secretion in Healthy Men," Journal of Gerontology, Vol. 43 (No. 6), pp. M163-169 (November 1988).	
	92	CONWAY, ET AL., "Randomized Clinical Trial of Testosterone Replacement Therapy in Hypogonadal Men," International Journal Of Andrology, Vol. 11 (No. 4), pp. 247-264 (August 1988).	
·	93	PLACE, ET AL., "Transdermal Delivery of Testosterone with Testoderm to Provide Normal Circadian Pattern of Testosterone," Annals New York Academy of Sciences, Vol. 618, pp. 441-449 (1991).	
	94	BHASIN, ET AL., "A Biodegradable Testosterone Microcapsule Formulation Provides Uniform Eugonadal Levels of Testosterone for 10-11 Weeks in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 1). pp. 75-83 (January 1992).	
	95	ARVER, ET AL., "Improvement of Sexual Function in Testosterone Deficient Men Treated for 1 Year with a Permeation Enhanced Testosterone Transdermal System," Journal Of Urology, Vol. 155 (No. 5), pp. 1604-1608 (May 1996).	Ŀ
	 96	LIAO, "Androgen Action: Molecular Mechanism and Medical Application," J. Formos Med. Assoc., Vol. 93 (No. 9), pp. 741-751 (September 1994).	
		CARLSTROM, ET AL., "Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function," International Journal Of Andrology (Vol. 13), pp. 67-73 (1990).	
	98	de LIGNIERES, ET AL., "Treatment of Male Hypogonadism by Topical Administration of Androgens," pp. 273-283 (1980).	
	99	DAVIDSON, ET AL., "Hormonal Changes and Sexual Function in Aging Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 57 (No. 1), pp. 71-77 (1983).	
		VERMEULEN, ET AL., "Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins," Maturitas, Vol. 7, pp. 281-287 (1985).	
7		MORRISON, "Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women," Psychopharmacology Bulletin, Vol. 33 (No. 2), pp. 293-296 (1997).	

Examiner	59A	Date While	
Signature	// 4/)	Considered 7/10 5/10 C	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 065(10:01)

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ed to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Act of 1999 To persons are reduction from the persons are reduction from the persons are reduction and the person and the person and the person are reduction are reduction are reduction are reduction and the person are reduction and the person are reduction are

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of Sheet

Complete if Known					
Application Number	09/703.753 グル こ				
	November 1, 2000				
First Named Inventor	Robert E. Dudley				
Group Art Unit	1617				
Examiner Name	S. Jiang				
Attorney Docket Number	01736349				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
59	102	JAFFE, ET AL., "Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men", Horm. Res., Vol. 41, pp. 215-217 (1994).	
	103	MORLEY, ET AL., "Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy," J. Lab. Clin. Med., Vol. 135 (No. 5), pp. 370-378 (May 2000).	
		MARIN, ET AL., "Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues," European Journal of Medicine, Vol. 1 (No. 6). pp. 329-336 (October 1992).	
	105	WANG, ET AL., "Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study," The Journal Of Endocrinology And Metabolism, Vol. 85 (No. 3), pp. 964-969 (March 2000).	
		KUHN, ET AL., "Percutaneous Androgen Treatment for Male Hypogonadism. Compared Efficacy of Testosterone and Dihydrotestosterone: Study of 40 Observations," Endocrinologie, Vol. 14 (No. 11), pp. 1031-1036 (1986) (English Translation)	
	107	HANDELSMAN, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Pellets in Man," Journal Of Clinical Endocrinology And Metabolism, Vol. 70 (No. 1), pp. 216-222 (1990).	
	108	STUENKEL, ET AL., "Sublingual Administration of Testosterone-Hydroxypropyl-b-Cyclodextrin Inclusion Complex Simulates Episodic Androgen Release in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 72 (No.5), pp. 1054-1059 (May 1991).	
	109	BHASIN, "Clinical Review 34 - Androgen Treatment of Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 6), pp. 1221-1225 (June 1992).	
	110	SALEHIAN, ET AL., "Pharmacokinetics, Bioefficacy, and Safety of Sublingual Testosterone Cyclodextrin in Hypogonadal Men: Comparison to Testosterone Enanthate - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 80 (No. 12), pp. 3567-3575 (1995).	
	111	MEIKLE, ET AL., "Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 5), pp. 1832-1840 (May 1996).	
599	112	WANG, ET AL., "Testosterone Replacement Therapy Improves Mood in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3578-3583 (1996).	

Examiner	\sim \sim	Date /	11/2/15	7 -
Signature	999	Considered	7/03/	
•			7 -77	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through-citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

O.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 199 control-number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) ----9- --- of-

Complete if Known 09/703.753 Application Number November 1, 2000 Filing Date Robert E. Dudley First Named Inventor Group Art Unit 1617 S. Jiang Examiner Name .Attorney_Docket_Number 01736349

	NON PATENT LITERATURE DOCUMENTS			
Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
59.Y	113	WANG, ET AL., "Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3654-3662 (1996).		
	114	McCLELLAN, ET Al., "Transdermal Testosterone," Drugs, Vol. 55 (No. 2), pp. 253-258 (February 1998).		
BHASIN, ET AL., "Therapeutic Perspective - Issues in Testosterone Replacement in Older Men, 115 Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 10), pp. 3435-3448 (1998).				
BEHRE, ET AL., "Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male 116 Hypogonadism: Phase I Studies," European Journal Of Endocrinology, Vol. 140. pp. 414-419 (199		BEHRE, ET AL., "Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male Hypogonadism: Phase I Studies," European Journal Of Endocrinology, Vol. 140. pp. 414-419 (1999).		
BEHRE, ET AL., "Long-Term Substitution Therapy of Hypogonadal Men with Transscr 117 Testosterone Over 7-10 Years," Clinical Endocrinology, Vol. 50, pp. 629-635 (1999). PARKER, ET AL., "Experience with Transdermal Testosterone Replacement 118 Therapy for Hypogonadal Men," Clinical Endocrinology, Vol. 50, pp. 57-62 (1998).				
		PARKER, ET AL., "Experience with Transdermal Testosterone Replacement Therapy for Hypogonadal Men," Clinical Endocrinology, Vol. 50, pp. 57-62 (1999).		
Years of Age," The Journal Of Clinical Endocrinology And Metabolism, Vol.84 (No. 6), pp. 119 1966-1972 (1999).		SNYDER, ET AL., "Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age," The Journal Of Clinical Endocrinology And Metabolism, Vol.84 (No. 6), pp.		
WANG, ET AL., "Comparative Pharmacokinetics of Three Doses of Percutaneous		WANG, ET AL., "Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men - A Clinical Research Center Study," Journal Of		
		LEIFKE, ET AL., "Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Vertebral Body Area and Paraspinal Muscle Area in Hypogonadal Men," European Journal of Endocrinology, Vol. 138, pp. 51-58 (1998).		
		BEHRE, ET AL., "Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men," Journal Of Clinical Endocrinology And		

Examiner	58CV	Date	4/	25/52
Signature		Considered	_//_	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, control number.

10

Sheet

Approved for use through 10/31/2002. OMB 0651:0031

Approved for use t

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Application Number 09/703.753

Filling Date November 1, 2000

First Named Inventor Robert E. Dudley Group Art Unit 1617

Examiner Name S. Jiang

Attorney Docket Number 01736349

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ2
39	123	DAMASSA, ET AL., "Sex Hormone-Binding Globulin and Male Sexual Development," Neuroscience And Biobehavioral Reviews, Vol. 19 (No. 2), pp. 165-175 (1995).	
	124	MORLEY, ET AL., "Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men," Metabolism, Vol. 46 (No. 4), pp. 410-413 (April 1997).	
		CUNNINGHAM, ET AL., "Plasma Sex Hormone-Binding Globulin Levels Decrease During the Second Decade of Life Irrespective of Pubertal Status," Journal Of Clinical Endocrinology And Metabolism, Vol. 58 (No. 5), pp. 915-918 (1984).	
	126	LEWIS, ET AL., "Serum 5a-Dihydrotestosterone and Testosterone Changes with Age in Man," ACTA Endocrinologica, Vol. 82, pp. 444-448 (1976).	
	127	HARDY, ET AL, "Endocrine Assessment of Impotence - Pitfalls of Measuring Serum Testosterone Without Sex-Hormone-Binding Globulin," Postgrad Medical Journal. Vol. 70. pp. 836-837 (1994).	
	128	DAVIDSON, ET AL., "Hormonal Replacement and Sexuality in Men," Clinics In Endocrinology And Metabolism, Vol. 11 (No. 3), pp. 599-623 (November 1982).	
	129	MANTZOROS, ET AL., "Contribution of Dihydrotestosterone to Male Sexual Behavior," British Medical Journal, Vol. 310, pp 1289-1291 (May 20, 1995).	
	130	MOORADIAN, ET AL., "Biological Actions of Androgens," Endocrine Reviews, Vol. 8 (No. 1), pp 1-28 (1987).	
		CUNNINGHAM, ET AL., "Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men," Journal Of Clinical Endocrinology and Metabolism, Vol. 70 (No. 3), pp. 792-797 (1990).	
	132	SKAKKEBAEK, ET AL., "Androgen Replacement with Oral Testosterone Undecanoate in Hypogonadal Men: A Double Blind Controlled Study," Clinical Endocrinology, Vol. 14, pp. 49-61 (1981).	
59J	133	de LIGNIERES, "Transdermal Dihydrotestosterone Treatment of Andropause," Annals Of Medicine, Vol. 25, pp. 235-241 (1993).	

Examiner	<0 Y	Date 4/Mon
Signature		Considered (/ 5//

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

MAR 2 8 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031,
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Jespond to a collection of information unless it contains a valid OMB

01736349

Under the Paperwork Reduction Act of 1995, no persons are required by espond control number.

of

11

Sheet

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 09/703.753

Filing Date November 1, 2000

First Named Inventor Robert E, Dudley

Group Art Unit 1617

Examiner Name S, Jiang

Attorney Docket Number

	NON PATENT LITERATURE DOCUMENTS				
Exan Initia		Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
9	acy	134	CHEMANA, ET Al., "Percutaneous Absorption of 5a-dihydrotestosterone in Man II. Percutaneous Administration of 5a-dihydrotestosterone in Hypogonadal Men with Idiopathic Haemochromatosis: Clinical, Metabolic and Hormonal Effectiveness," International Journal Of Andrology, Vol. 5, pp. 595-606 (1982).		
		135	McCLURE, ET AL., "Hypogonadal Impotence Treated by Transdermal Testosterone," Urology, Vol. XXXVII (No. 3), pp. 224-228 (March 1991).		
		136	GOOREN, "Androgen Levels and Sex Functions in Testosterone-Treated Hypogonada Men," Archives Of Sexual Behavior, Vol. 16 (No. 6), pp. 463-473 (1987).	1	
		137	TSITOURAS, "Effects of Age on Testicular Function," Endocrinology And Metabolism Clinics, Vol. 16 (No. 4), pp.1045-1059 (December 1987).		
		138	ANDERSON, ET AL., "The Effects of Exogenous Testosterone on Sexuality and Mood of Normal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 75 (No. 6). pp.1503-1507 (1992).		
	·	139	KNUSSMANN, ET AL., "Relations Between Sex Hormone Levels and Sexual Behavior in Men," Archives Of Sexual Behavior, Vol. 15 (No.5), pp. 429-5 (1986).		
		140	BANCROFT, "Endocrinology of Sexual Function," Clinics In Obstetrics And Gynecology, Vol. 7 (No. 2), pp. 253-281 (August 1980).		
		141	BAGATELL, ET AL., "Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 78 (No. 3), pp. 711-716 (1994).		
WEINBAUER, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate a		WEINBAUER, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate and Dihyrotestosterone Enanthate in Non-Human Primates," ACTA Endocrinologica (COPENH), Vol. 122 (No. 4), pp. 432-442 (1990).			
			"Sexual Dysfunction in the Male - Sexual Arousal Disorder," The Merck		
-	\dashv	143	Manual, Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992).	$\vdash\dashv$	
S	29		JOCKENHOVEL, ET AL., "Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men," Clinical Endocrinology, Vol. 45, pp. 61-71 (1996).		

Examiner Date 4/24/07			<u> </u>	
	Examiner Signature	Saly		4/2/02
Signature 1 Considered 1/1 Considered	Signature I		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of control number.

Sheet

PTO/SB/08B (10-01)

Approved for through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ired to respond to a collection of information unless it contains a valid OMB

01736349

Complete if Known Substitute for form 1449B/PTO **Application Number** 09/703.753 INFORMATION DISCLOSURE Filing Date November 1. STATEMENT BY APPLICANT First Named Inventor Robert E. Dudlev Group Art Unit (use as many sheets as necessary) **Examiner Name** S. Jiana 12

Attorney Docket Number

· · ·	NON PATENT LITERATURE DOCUMENTS	_
Examiner Cite No.1		
14:	BEHRE, ET AL., "Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester," Journal Of Endocrinology And Metabolism," Vol. 75 (No. 5), pp. 1204-1210 (1992).	ſ
140	SCHURMEYER, ET AL., "Comparative Pharmacokinetics of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men," International Journal of Andrology, Vol. 7, pp. 181-187 (1984).	Γ
147	MAZER, ET Al., "Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men," Journal of Controlled Release, Vol. 19, pp. 347-361 (1992).	
148	COFRANCESCO, Jr., ET AL., "Transdermal Testosterone Delivery Systems," The Endocrinologist, Vol. 6 (No. 3), pp. 207-213 (1996).	
149	BROCKS, ET Al, "Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose," Journal of Clinical Pharmacology, Vol. 36, pp. 732-739 (1996).	
150	ARVER, ET AL., "Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men." Clinical Endocrinology. Vol. 47, pp. 727-737 (1997).	
151	MEIKLE, ET Al., "Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 43, pp. 449-457 (1996 Wiley-Liss, Inc.).	
	BALS-PRATSCH, ET AL., "Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year," ACTA Endocrinologica (COPENH), Vol. 118, pp. 7-13 (1988)	
\	CAREY, ET AL., "Transdermal Testosterone Treatment of Hypogonadal Men," The Journal of Urology, Vol. 140, pp. 76-79, (July 1988).	
154	CUNNINGHAM, ET AL., "Testosterone Transdermal Delivery System," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 42, pp. 437-447 (1996 Wiley-Liss, Inc).	
	Product-Information Testoderm-TTS, Physicians' Desk Reference; Alza pp.	

Examiner Date Signature Considered

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

3. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ed to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Act of 1995 no persons are red control number. Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) 13

Sheet

Co	7	
Application Number	09/703.753	13
	November 1, 2000	- 2
First Named Inventor	Robert E. Dudley	'20
Group Art Unit	1617	10
Examiner Name	S. Jiang	40
Attorney Docket Number	01736349	Ĺ

<u> </u>	NON PATENT LITERATURE DOCUMENTS					
Exa Initi	miner als*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
52	2()	156	YU, ET AL., "Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men," Journal of Clinical Pharmacology, Vol. 37, pp. 1139-1145 (1997).			
		157	YU, ET AL., "Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application," Journal of Clinical Pharmacology, Vol. 37, pp. 1129-1138 (1997).			
			WALTERS, "Penetration Enhancers and Their Use in Transdermal Therapeutic Systems," pp. 202-227 (1990).			
		159	GENNARO, "Remington: The Science and Practice of Pharmacy, 20th Edition," Chapter 44, pp. 842-843 (2000).			
		160	JARKANDER-ROLFF, ET AL., "Transdermal Application of A Testosterone Gel - A Pharmacokinetic Study."			
		161	TIRASSA, ET AL., "High-Dose Anabolic Androgenic Steroids Modulate Concentrations of Nerve Growth Factor and Expression of its Low Affinity Receptor (p75-NGFr) in Male Rat Brain," Journal of Neuroscience Research. Vol. 47 (No. 2). pp. 198-207 (January 15, 1997).			
		162	VELDHUIS, ET AL., "Muting of Androgen Negative Feedback Unveils Impoverished Gonadotropin-Releasing Hormone/Luteinizing Hormone Secretory Reactivity in Healthy Older Men," The Journal of Clinical Endocrinology & Metabolism. Vol. 86 (No. 2), pp. 529-535. (2001)			
		163	MILLER, ET AL., "Androgen Deficiency in Women with Hypopituitarism," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No.2), pp. 561-567 (2001).			
		164	KAO, ET AL., "Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: in vitro Studies with Mouse Skin in Organ Culture," Journal of Pharmacology and Experimental Therapeutics, Vol. 241 (No. 2), pp. 482-487 (May 1987).			
			FINDLAY, ET AL., "Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 68 (No. 2), pp. 369-373 (February 1989).			
5	a)	/	ERNESTI, ET AL., "Absorption and Metabolism of Topically Applied Testosterone in an Organotypic Skin Culture," Skin Pharmacology, Vol. 5 (No. 3). pp. 146-153 (1992).			

Examiner	2 a	Date 1/1/2015
Signature		Considered P//03/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of control number.

PTO/SB/08B (10-01)
Approved for through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE red to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO	TA TRADEMA
INFORMATION	
STATEMENT B	Y APPLICANT

Application Number 09/703.753
Filling Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

Sheet 14 of 21

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the T2 Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initiats* number(s), publisher, city and/or country where published. CHOI, ET AL., "Transdermal Dihydrotestosterone Therapy and its Effects on Patients with Microphallus," Journal Of Urology, Vol. 150 (No. 2) (Part 2), pp. 657-660 (August 1993) 168 Testosterone, Chapters 1, 6-16 (1999). TSAI, ET AL., "Metabolic Approaches to Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors." Journal of Pharmaceutical Sciences, Vol. 85 (No. 6), pp. 643-648 (June 1996). MEIKLE, ET AL., "Familial Effects on Plasma Sex-Steroid Content in Man: Testosterone, Estradiol 170 and Sex-Hormone-Binding Globulin," Metabolism, Vol. 31 (No. 1), pp. 6-9 (January 1982). SHANBHAG, ET AL., "The Temperature Dependence of the Binding of 5 Alpha-Dihydrotestosterone, Testosterone and Estradiol to the Sex Hormone Globulin (SHBG) of Human Plasma," J. Steroid Biochem., Vol. 24 (No. 2), pp. 549-555 (February 1986). BELGOROSKY, ET AL., "Changes in Serum Sex Hormone-Binding Globulin and in Serum Non-Sex Hormone-Binding Globulin-Bound Testosterone During Prepuberty in Boys," J. Steroid Biochem., Vol. 27 (Nos. 1-3), pp. 291-295 (1987). KORENMAN, ET AL., "Androgen Therapy of Hypogonadal Men with Transscrotal Testosterone Systems," American Journal Of Medicine, Vol. 83 (No. 3), pp. 471-478 (September 1987) MITCHELL, ET AL., "Age Related Changes in the Pituitary-Testicular Axis in Normal Men; Lower Serum Testosterone Results from Decreased Bioactive LH Drive," Clinical Endocrinology (OXF), Vol. 42 (No. 5), pp. 501-507 (May 1995). NANKIN, ET AL., "Decreased Bioavailable Testosterone In Aging Normal and Impotent Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 6), pp. 1418-1420 (December 1986) TENOVER, ET AL., "The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clomiphene Citrate," Journal Of Clinical Endocrinology And Metabolism, Vol. 65 (No. 6), 176 pp. 1118-1126 (December 1987). WINTERS, ET AL., "The Gonadotropin-Suppressive Activity of Androgen is Increased in Elderly Men," Metabolism, Vol. 33 (No. 11), pp. 1052-1059 (November 1984).

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
D.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1913 no persons are red control number.

SUBSTITUTE for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			TRADE	Со	mplete if Known		
			CLOSUBE	Application Number	09/703.753		
				Filing Date	November 1, 2000		
			PPLICANT	First Named Inventor	Robert E. Dudley	-	
				Group Art Unit	1617		
(use as many sheets as necessary)		Examiner Name	S. Jiang				
Sheet							
				NON P	ATENT LITERATURE DO	DCUMENTS	;
Examiner	include name of the author (in CAPITAL LETTERS) title of the article (when appropriets) title of the					-,	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
<i>39</i> ()	178	MEIKLE, ET AL., "Enhanced Transdermal Delivery of Testosterone Across Nonscrotal Skin Produces Physiological Concentrations of Testosterone and Its Metabolites in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 3), pp. 623-628 (March 1992).	
	179	WINTERS, ET AL., "Serum LH Concentrations in Hypogonadal Men During Transdermal Testosterone Replacement Through Scrotal Skin: Further Evidence That Ageing Enhances Testosterone Negative Feedback. The Testoderm Study Group," Clinical Endocrinology (OXF), Vol. 47 (No. 3), pp. 317-322 (September 1997).	
		BOYLE, ET AL., "Serum Testosterone Measurements," American Journal Of Clinical Pathology, Vol. 81 (No. 6), pp. 754-761 (June 1984).	
	181	HOLOWNIA, ET AL., "A Clinical Evaluation of A Direct Radioimmunoassay of Testosterone," Clinical Chimica Acta, Vol. 214 (No. 1), pp. 31-43 (January 31, 1993).	
		BELGOROSKY, ET AL., "Progressive Decrease in Serum Sex Hormone-Binding Globulin from Infancy to Late Prepuberty in Boys," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 2), pp. 510-512 (August 1986).	
	183	VALERO-POLITI, ET AL., "Daily Rhythmic and Non-Rhythmic Variations of Follitropin, Lutropin, Testosterone, and Sex-Hormone-Binding Globulin in Men," Eur. J. Clin. Chem. Clin. Biochem., Vol. 34 (No. 6), pp. 455-462 (June 1996).	
18		VALERO-POLITI, ET AL., "Annual Rhythmic Variations of Follitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men," Clinica Chimica Acta, Vol. 271 (No. 1), pp. 57-71 (March 9, 1998).	
		LONGCOPE, ET AL., "Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 71 (No. 6), pp. 1442-1446 (December 1990).	
	- 1	BELGOROSKY, ET AL., "Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones," J. Steroid Biochem., Vol. 18 (No. 6), pp. 783-787 (June 1983).	
	Ì	LEWIS, ET AL., "Proceedings: Age-Related Changes in Serum Saplha-dihydrotestosterone and Testosterone in Normal Men," Journal Of Endocrinology, Vol. 67 (No. 2), pg. 15P (November 1975).	
599		PIRKE, ET AL., "Age Related Changes and Interrelationships Between Plasma Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males," ACTA Endocrinologica (COPENH), Vol. 74 (No. 4), pp. 792-800 (December 1973).	,

Examiner Signature Date 4/24/57				
	Examiner	$\bigcirc 0$	Date	0/10-7-
Signature 1 Considered // 3/	Signature	590	Considered	4/10/80

^{*}EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0034 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE quired to respond to a collection of information unless it contains a valid OMB of the contains a valid OMB of th Under the Paperwork Reduction Act of 1895, no persons and control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

09/703.753 **Application Number** November 1, 2000 Filing Date **First Named Inventor** Robert E. Dudley Group Art Unit 1617 **Examiner Name** S. Jiano

Complete if Known

(use as many sheets as necessary) 16 Sheet

Attorney Docket Number 01736349

		NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.1		number(s), publisher, city and/or country where published.					
99 189		MASTERS, ET AL., "Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol," Clinical Chemistry, Vol. 35 (No. 6), pp. 979-984 (June 1989).					
WANG, ET AL., "Salivary Testosterone in Men: Further Evidence of a Direct Correlatio		WANG, ET AL., "Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 53 (No. 5), pp. 1021-1024 (November 1981).					
	191	ZMUDA, ET AL., "Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men," Metabolism, Vol. 45 (No. 8), pp. 935-939 (August 1996).					
	192	GAIDANO, ET AL., "Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty," Clinical Chimica Acta, Vol. 100 (No. 2), pp. 91-97 (January 15, 1980).					
193 C		Definition of Isopropyl Myristate (5103), The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals, Eleventh Edition, p. 821 (1989).					
		GENNARO, ET AL., Remington's Pharmaceutical Sciences, Eighteenth Edition, pp. 1305, 1314-1315 (1990).					
		LANGTRY, ET AL., "Sildenafil - A Review of its Use in Erectile Dysfunction," Drugs, Vol. 57 (No. 6), pp. 967-989 (1999).					
196 Co		MORELAND, ET AL., "Sildenafil, A Novel Inhibitor of Phosphodiesterase Type 5 In Human Corpus Cavernosum Smooth Muscle Cells," Life Sciences, Vol. 62 (No. 20) pp. PL309-318 (1998).					
FAI Bin		FAHRNER, ET AL., "Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG)," International Journal Of Sports Medicine, Vol. 19 (No. 1). pp. 12-15 (January 1998). [Abstract]					
	198	BARTSCH, "Interrelationships Between Sex Hormone-Binding Globulin and Testosterone, 5 alpha-Dihydrotestosterone and Oestradiol-17 beta in Blood of Normal Men," Maturitas, Vol. 2 (No. 2), pp. 109-118 (July 1980). [Abstract]					
SPG		WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," Clinical Endocrinology, Vol. 54, pp. 1-13 (2001).					

Examiner	CUV	Date	4	120	10	>
Signature	<i>y y</i>	Considered		00		_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Ac control number.

TRADEM Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) 17

Complete if Known					
Application Number	09/703.753				
	November 1, 2000				
	Robert E. Dudley				
Group Art Unit	1617				
Examiner Name	S. Jiang				
Attorney Docket Number	01736349	7			

		NON PATENT LITERATURE DOCUMENTS				
Examiner Cite No.						
99 20		GOOREN, "A Ten-Year Safety Study of the Oral Androgen Testosterone Undecanoate," J. Androl., Vol. 15 (No. 3), pp. 212-215 (May-June 1994). [Abstract]				
	201	MAZER, "New Clinical Applications of Transdermal Testosterone Delivery in Men and Women," J. Controlled Release, Vol. 65 (No. 1-2), pp. 303-315 (March 1, 2000). [Abstract]				
ITOH, ET AL., "The Assessment of Bioavailable Androgen Levels from the Serum F		1TOH, ET AL., "The Assessment of Bioavailable Androgen Levels from the Serum Free Testosterone Level, "Nippon Naibunpi Gakkai Zasshi, Vol. 67 (No. 1), pp. 23-32 (January 20, 1991). [Abstract]				
	203	Male Hormone Patch Approved, Nupharm, http://www.nupharm.com/malehorm.htm.				
204		"SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available," International Association of Physicians in AIDS Care, thttp://www.iapac.org/clinmgt/compnews/sb061297.html (June 12, 1997).				
	205	"Impotence Treatments," Impotence World Association, http://www.impotenceworld.org/treatment.htm (2000).				
207		"Andro Gel," Netrition, http://www.netrition.com/andro_gel_page.html (1997-1998).				
		"Cellegy Pharmaceuticals Market Opportunities," CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market.html (1997).				
		"Prospectus - Cellegy Pharmaceuticals, Inc.," OPPENHEIMER & CO., pp. 1-4, 21-28 (1997).				
. \	209	The Testosterone Source, http://www.testosteronesource.com (1998).				
59Q		BONNEY, "Hormone Replacement Therapy for Men," American Clinical Laboratory, http://iscpubs.com/pubs/acl/acl1-197.html—(November/December1997).				

Examiner	$\leq a \sim$	Date	Waston,
Signature		Considered	7/10/02

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it contains a valid OMB MAR 2 8 2002 W Under the Paperwork Reduction Ad control number.

Substitute for form 1449B/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	09/703.753	
	Filing Date	November 1, 2000	
STATEMENT BY APPLICANT	First Named Inventor	Robert E. Dudley	
	Group Art Unit	1617	
(use as many sheets as necessary)	Examiner Name	S. Jiang	
Sheet 18 of 21	Attorney Docket Number	01736349	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	itials No.1 nem (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	21-1	Andropausal, Los Gatos Longevity Institute, http://www.antiaging.com/andropause.html (1998).			
	212	TestoCreme - A Natural Transdermal Testosterone Replacement Therapy,			
99()	213	WANG, ET AL., "Pharmacokinetics Of Transdermal Testosterone Gel in Hypogonada Men," ENDO '98 SUBMISSION PROGRAM, 1998N ABSTRACT FORM.	1		
SWERDLOFF, ETAL., "Long Term Pharmacokinetics of Transdermal Testosterone Gel Versu Testosterone Patch in Hypogonadal Men," 2347 Male Reproductive Poster Session, Board 578 214 22, 2000).					
	215	WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," 2348 Male Reproductive Poster Session, Board 579 (June 22, 2000).			
	216	WANG, ET AL, "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," Basic Science: Reproduction-Gonadal Control (Male), Male Reproduction Oral Session, No. 1360 (June 24, 2000).			
	217	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, wwwINGHD:com (August 19, 1998).			
S90	218	RIGGS, "Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel," Unimed News Release, pp. 1-2 (March 31, 1997).			
	219	Androgel-1% (testosterone gel) CIII.; www.Androgel.com, pp. 1-2.			
ST	220	VERGEL, "Anabolic Steroids: A Practical Guide," CRIA Update, Vol. 7 (No. 3) (Summer 1998).			
	-22-1-	MOONEY, "Frequencey of Administration - Testosterone & Nandrolone," Vol. 1 (No4), www.medibolics.com-(Downloaded-10/8/98).			

Examiner Signature	999	Date Considered	4/25/52
~			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English tanguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for through 10/31/2002. OMB 0651-0031
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	r form 1449B/PTO	TRADE AN	S Co	mplete if Known	=======================================	E	1
INEOE	RATION	DISCLOSURE	Application Number	09/703.753	\mathbb{C}	5	-
INFOR	CIVIATION	DISCLUSURE	Filing Date	November 1, 200	0==		Ī
STATEMENT BY APPLICANT			First Named Inventor	Robert E. Dudley	ří	36	(
•		, and Elopater	Group Art Unit	1617			
	(use as many she	eets as necessary)	Examiner Name	S. Jiang	LEI) (
Sheet	19	of 21	Attorney Docket Number	01736349		~).	7

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue T ² number(s), publisher, city and/or country where published.
590	22/2	Anabolic Steroids, Project Inform, Anabolic Steroids Quick Sheet (December 1997).
My	223	"Anabolic Steroid Boosts Weight," GMHC Treatment Issues, Vol. 10, No. 9 (September 1996).
	224	Anabolic Steroids, Project Inform Hotline Handout, www.projinf.org. (Downloaded-10/8/98).
	-225	Anabolic Steroids - A Simple Facts Sheet From The Network, www.network/simple/steroids (Downloaded 10/27/98).
	-226	USP Drug Information - Anabolic Steroids (Systemic), MayoClinic,
500.	227	MOONEY, "Anabolic Steroids For AIDS Therapy: Differences Between Analogs," No. 1, www.digiweb.com. (July 1998).
	22 8	Testocreme - No Shots, No Pills, No Patches, www.testoereme:com (Downloaded-7/10/00).
AV	229	"ENDO 99: Testosterone Patch Effective For Diminished Sexual Function in Surgically Menopausal Women," www.pslgroup.com-(June 15, 1999).
A	230	"Data Supports Safety of Estratest For Men," Doctor's Guide, www.pslgroup.eom (March 9, 1998).
SD	231	"Testosterone's Role in the Female Sex Drive," USA Today News,
	232	"Alternative to Viagra For Women?," www.mdhealthline.com-(Downloaded

Examiner	591	Date Chlostin	
Signature		Considered	
_			_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1997 to persons are required to respond to a collection of information unless it contains, a valid OMB control number.

00.11.01.110111			***	<u> </u>		L. r	
Substitute fo	r form 1449B/PTO		TRADEMARIN	Со	mplete if Known	兰	P
INFO	RMATION	DISC	LOSUBE	Application Number	09/703.753	닭	3¢
				Filing Date	November 1, 2000	Z.)
STATI	EMENT BY	Y AP	PLICANT	First Named Inventor	Robert E. Dudlev	m	, (
				Group Art Unit	1617	بد	
	(use as many she	eets as n	ecessary)	Examiner Name	S. Jiang	S)	'n
Sheet	20	_of_	21	_Attorney Docket Number	01736349	2	2 5

 -	1	NON PATENT LITERATURE DOCUMENTS	<u>う</u>
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s). publisher, city and/or country where published.	
2911	233	"Never Too Buff," Time Europe, www.time.com, Vol. 155 (No. 16) (April 24, 2000).	
	234	Gefael, Graeme's Testosterone Page, www.voyager.co.nz (5/42/00).	
	235	Estrogel, www.netdoktor.dk/medicin/Pakta/Estrogel (Downloaded 6/26/01).	
	236	La Sexualite, L'Androgel, Le Gel Miracle, www.aci-multimedia.net/feminin/androgel (Downloaded-5/9/01)	
ic i ni i na i na i na i na i na i na i	237	Stehli, et al., Info, Info Androgel, www.mageos:ifrance.com/nade38/androgel (Downloaded 5/9/01):	
	238	CHERRIER, ET AL., "T-Gel Study: Cognitive Effects of Exogenous Testosterone Manipulation in Hypogonadal-Men" (6/7/99)	Ī
	c. 4	"Bentley Pharmaceuticals Annouces Research and Licensing Agreements For Intranasal Pain Management and Topical Hormone Replacement Therapy," www.bentleypharm.com (downloaded -1/17/01).	
and the second of the second	240	"Testosterone Gel May Help Men with Low Sex Drive," WRAL ONLINE, http://www.wral-tv.com/features/healthteam/1997/0814-tgel/ (August 14, 1997).	
erakuman itong den Padet		"Testocreme Transdermal Testosterone Is New," Preventive Medicine Clinic Of Monterey, http://www.wellnessmd.com/testo.html	
		"SEDA Testadoro Terrolomo I C.1 D.	
	242	"SEPA Testosterone Transdermal Gel Receives Application by FDA," Doctor's Guide Global Edition, http://pslgroup.com/dg/123aa.htm.(January-15, 1997).	300
		Press Release - 10/21/99 - MacroChem Awarded U.S. Patent Covering Transdermal Hormone Replacement Incorporating Proprietary SEPA Technology and Hormonally Active Drugs Such as Testosterone, Estradiol and Progesterone,	
	243	http://www.mchm.com/press/pr24.asp (October 21, 1999).	ł

		/	
Examiner	120	Date (//2A	700
Signature	79 Y	Considered 7/05/	02

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ed to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Act of control number.

Substitute fo	or form 1449B/PTO	_	TRADEMARK	Со	mplete if Known	S. P
INEO	ORA A TION	Die	CLOSURE	Application Number	09/703.753	C 25
INFO	ZIVIATION	פוע	CLUSURE	Filing Date	November 1, 2000	1/2
STATEMENT BY APPLICANT				First Named Inventor	Robert E. Dudley	14
				Group Art Unit	1617	<i>'</i> 2
	(use as many si	heets a	s necessary)	Examiner Name	S. Jiano	(C)
Sheet	21	of	21	Attorney Docket Number	01736615	6

		Include name of the outbookin CARITAL LETTEROLAND of the outbooking to
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	244	AndrosteDERM, http://www.gethuge.net/androderm1.htm.
***	245	MANOS, "FDA Approves Gel to Treat Low Testosterone Levels," www.testocreme.com (Downloaded 5/09/01).
······································	2 46	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www.INCIID.com (August 19, 1998).
30	247	LACAYO, "Are You Man Enough?," Time Europe, www.Time.com, Vol. 155, No. 16 (April 24, 2000).
	248	"MacroChem Accelerates Development of Top For Impotence," www.pslgroup.com (April 1'0, 1'997).
79Y)	/ 249	BRADLEY, "Potential Expanded Indications for Androgen Treatment," The Endocrine Society, No. 166 (ENDO 2000).
	250	WANG, ET AL., "New Androgen Formulations," The Endocrine Society, No. 167 (ENDO 2000).
	251	WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," The Endocrine Society, No. 1360 (ENDO 2000).
	252	WITTERT, ET AL., "Androgen Deficiency in Aging Men," The Endocrine Society, No. 1626 (ENDO 2000).
		BRILL, ET AL., "Single and Joint Impact of One-Month of Transdermal Testosterone (T) and/or Recombinant Human Growth Hormone (rhGH) Supplementation on Body Composition, Strength, Balance, Function and Muscle IGF-I and Androgen Gene Expression in Healthy Older Men: A Prospective Randomized Double-Blind Crossover," The Endocrine Society, No. 1647 (ENDO 2000).

Examiner	200	Date	1200
Signature	19	Considered	 MOL

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English tanguage Translation is attached. \(\)

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Co	Complete if Known						
Application Number	09/703,753	_	·				
Filing Date	November 1, 2000		i				
First Named Inventor	Robert E. Dudley	Ñ					
Art Unit	1617	333					
Examiner Name	S. Jiang	ກັບ	1				
Attorney Docket Number	01736349		フ				

			U.S. PAT	ENT DOCUMENTS	= 0
Examiner Initials*		Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
591	1	us-4496556	01/29/1985	Orentreich	0,
	2	us-4695465	09/22/1987	Kigasawa, et al.	Sum
	3	us-4863970	09/05/1989	Patel, et al.	
	4	us-4946870	08/07/1990	Partain, et al.	
	5	us-5053227	10/01/1991	Chiang, et al.	
	6	us-5059603	10/22/1991	Rubin	
	7	us-5152997	10/06/1992	Ebert, et al.	
	8	us-5256652	10/26/1993	El-Rashidy	
	9	us-5324521	06/28/1994	Gertner, et al.	<u> </u>
	10	us-5332577	07/26/1994	Gertner, et al.	II :
	11	us-5340586	08/23/1994	Pike, et al.	
	12	us-5346901	09/13/1994	Bell, et al.	罗龙(
	13	us-5362497	11/08/1994	Yamada, et al.	
	14	us-5413794	05/09/1995	Suzuki, et al.	2 6 .
	15	us-5460820	10/24/1995	Ebert, et al.	16 ≥ 4
	16	US- 5550107	08/27/1996	Labrie	S E r
	17	US- 5648350	07/15/1997	De Lignieres	
	18	US-5719197	02/17/1998	Kanios, et al.	/290
1	.19	us-5723114	03/03/1998	Thornfeldt, et al.	
7 (4)	20	US- 5744162	04/28/1998		

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures. Appear	T			
					C				
						1			
			· ·			77			
						╄			
						┢			
					60	12			
					0/29	7			
					29				

Examiner	SO	Date	6/211	1 2 2
Signature		Considered	31,44	0

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols and indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

21 of Sheet

Co	omplete if Known
Application Number	09/703.753
Filing Date	November 1, 2000
	Robert E. Dudlev
Art Unit	1617
Examiner Name	S. Jiang
Attorney Docket Number	01736349

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*		Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
594 X	21	us-5785991	07/28/1998	Burkoth, et al.	
10	22	US- 5788983	08/04/1998	Chien, et al.	
	23	US-5855905	01/05/1999	Oettel, et al.	
	24	us-5877216	03/02/1999	Place, et al.	
L_	25	us-5932227	08/03/1999	Higo, et al.	
	26	us-5955455	09/21/1999	Labrie	·
	27	us-6010716	01/04/2000	Saunal, et al.	
	28	us-6036977	03/14/2000	Drizen, et al.	0
	29	us-6037346	03/14/2000	Doherty, et al.	
	30	us-6075028	06/13/2000	Graham	<u> </u>
	31	us-6077841	06/20/2000	Sui, et al.	N)
	32	us-6087362	07/11/2000	El-Rashidy	<u>—</u>
	33	us-6087368	07/11/2000	Macor, et al.	6
	34	us-6103765	08/15/2000	Neal	160 2c
	35	us-6124461	09/26/2000	Shoemaker	9 0
	36	us-6127363	10/03/2000	Doherty, et al.	29
<u> </u>	37	us-6139873	10/31/2000	Hughes, Jr., et al.	8
_[/38	us-6156753		Doherty, et al.	
bol	39	us-6238284 B1		Dittgen, et al.	
599	40	us-6248363 B1	06/19/2001	Patel, et al.	

		FOR	EIGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages or Relevant Figures Appear	T®
					웃	
					С	ΙV
					111	ĸ
					<u> </u>	
					- - - - -	2
		·			8	00
	L_				- 2	7
	L			<u></u>	90	

Examiner Signature	SAY	Date Considered	5/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 09/703,753

Filing Date November 1, 2000

First Named Inventor Robert E. Dudley

Art Unit 1617

Examiner Name S. Jiang

Attorney Docket Number 01736349

21

3

Sheet

		<u>.</u>		U.S. PAT	ENT DOCUMENTS	
Examine Initials*	1.7.	Document Number Number - Kind Code ² (ii	_	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
591	41	us-6251436	B1	06/26/2001	Drizen, et al.	
10	42	us-6266560	B1	07/24/2001	Zhang, et al.	
	43	US-6267985	<u>B1</u>	07/31/2001	Chen, et al.	_
	44	US-6277884	<u>B1</u>	08/21/2001	de Tejada	<u> </u>
	45	US-6294192	<u>B1</u>	09/25/2001	Patel, et al.	C 유 I
	46	US-6294550	B1	09/25/2001	Place, et al.	<u> </u>
	47	US-6299900	<u>B1</u>	10/09/2001	Reed, et al.	
\vdash	48	US-6306841	B1	10/23/2001	Place, et al.	
	49	US-6323242	<u>B1</u>	11/27/2001	Mueller	-
	50	US-6331543	B1	12/18/2001	Garvey, et al.	8 B r
	51	US-010018073	Al	08/30/2001	Dittgen, et al.	72
	52	US-010023261	Al	09/20/2001	Ryoo, et al.	e U
	53	US-010033870	<u>A1</u>	10/25/2001	Luo, et al.	3
	54	US-010036483	A1	11/01/2001	Luo, et al.	
	55	US-010051166	Al	12/13/2001	Luo, et al.	
Suy	56		$\mathbf{A}1$	12/13/2001	Place, et al.	
		US-				
		US-		<u> </u>	<u> </u>	
	ļ	US-				
		US-				· · · · · · · · · · · · · · · · · · ·

		FORE	IGN PATENT D	OCUMENTS		-
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Ţ6
<94)	57	wo 92/15289 A1	09/17/1992	Mantelle	E	
10	58	WO 93/25168 A1	12/23/1993	Heiber, et al.	三 王	
	59	WO 94/21230 A1	09/29/1994	Elias, et al.	CE	d٦
	60	wo 94/28902 A1	12/22/1994	Ellis, et al.	ΞN	R
	61	WO 96/16644 A1	06/06/1996	Campbell, et al.	TB	4
	62	wo 96/16657 A1	06/06/1996	Cambell, et al.		9
	63	wo 96/27372 A1	09/12/1996	Allen	16	2
	64	wo 96/36339 A2	11/21/1996	Mantzoros	00	00
	65	wo 97/03985 A1	02/06/1997	Daugan, et al.	/2	٦
S (Y)	66	wo 97/24148 A1	07/10/1997	Chen, et al.	90	

Examiner Signature	SIV	Date Considered	ک	/2 l	102	ر

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

KECEIVED

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO **Application Number** 09/703.753 INFORMATION DISCLOSURE November 1, 2000 Filing Date STATEMENT BY APPLICANT **First Named Inventor** Robert E. Dudley Art Unit <u> 1617</u> (use as many sheets as necessary) S. Jiang **Examiner Name** Sheet Attorney Docket Number 01736349

		U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Document Number Number-Kind Code ² (if known,	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US-			
	US-			크
	US-	···		
	US-		·	I P F
	US-			
	US-			2 ~ (
	US-			
	US-			20 or 1
	US-			6 6 3
	US-			0 2
	US-			600/29
	US-			8
	US-			
	 US-			
	US-			

		FORI	EIGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
591	67	wo 97/43989 A1	11/27/1997	Portman, et al.		
	68	WO 98/34621 A1	08/13/1998	Rako		
-	69	wo 99/24041 A1	05/20/1999	Mak, et al.	E	
+	70	wo 99/66870 A1	12/29/1999	Fotinos	웃	
	71	WO 00/45795 A2	08/10/2000	Lulla, et al.	O P	
	72	wo 00/76522 A1	12/21/2000	Rosario-Jansen, et al.		
	73	WO 01/52823 A2	07/26/2001	Kanios		
	<u>74</u>	wo 01/76608 A1	10/18/2001	Lipp, et al.		
	75	EP 0196769 A2	10/08/1996	Chien, et al.	8 3	
<u> </u>	76	EP 0483105 B2	04/29/1992	Cleary	-	
					2	
Examine Signatu				Date Considered	5/2/82	(

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 21

Complete if Known						
Application Number	09/703.753					
Filing Date	November 1, 2000					
First Named Inventor	Robert E. Dudley					
Art Unit	1617					
Examiner Name	S. Jiang					
Attorney Docket Number	01736349					

		U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No. 1 Number-Kind Code 2 (if k	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US-			
	US-			m
	US-			<u> </u>
	US-			O A
ì	US-			<u> </u>
	US-			
	US-			70 G
	US-			
	US-			20.00
	US-			9,2
	US-			900
	US-			8
	US-			
	US-		**	

		FO	REIGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (If known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Ţŝ
581	77	EP 0491076 A	1 06/24/1992	Patel, et al.	<u> </u>	
70	78	EP 0513832 A	1 11/19/1992	LAMIGO	AF C	
Sat	79	EP 0581587 A	2 02/02/1994	Kobayashi, et al.		
· V			<u> </u>			
,				ļ	മ ഒ	
					6 2	K
				<u> </u>	000 4000	m
				<u> </u>	129	Ь.;
	<u> </u>			 	8 '	ب

Examiner Signature Date Considered 5/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449B/PTO **Application Number** 09/703.753 INFORMATION DISCLOSURE Filing Date November 1, 2000 STATEMENT BY APPLICANT First Named Inventor Robert E. Dudley Group Art Unit 1617 S. Jiang (use as many sheets as necessary) **Examiner Name** of Attorney Docket Number 01736349 Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
59	80	RINGHAM, ET AL., "Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel in Hypogonadal Men," Unimed Pharmaceuticals (October 31, 2000).	JEC 1
	81	LONGSTRETH, ET AL., "Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment," Unimed Pharmaceuticals (October 31, 2000).	GEN
	82	KAUFMAN, "Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation," International Journal of Impotence Research," Vol. 12 (Supplement 3), p. S75 (B9) (September 2000).	7
	83	JORDAN, "Allergy and Topical Irritation Associated With Transdermal Testosterone Administration: A Comparison of Scrotal and Nonscrotal Transdermal Systems," American Journal of Contact Dermatitis, Vol. 8 (No. 2), pp. 108-113 (June 1997).	00/290
	84	GOUCHIE, ET AL., "The Relationship Between Testosterone Levels and Cognitive Ability Patterns," Psychoneuroendocrinology, Vol. 16 (No. 4), pp. 323-334 (1991).	_
- ·		DOBS, ET AL:, "Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison-with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 10), pp. 3469-3478 (1999).	ECH C
	86	PERSKY, ET AL., "Plasma Testosterone Level and Sexual Behavior of Couples," Archives of Sexual Behavior, Vol. 7 (No. 3), pp. 157-173 (May 1978).	CENTER
	87	AHMED, ET AL., "Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism," Journal Of Clinical Endocrinology And Metabolism, Vol. 66 (No. 3), pp. 546-551 (March 1988).	2/000
	88	BALS-PRATSCH, ET AL., "Transdermal Testosterone Substitution Therapy for Male Hypogonadism," The Lancet, Vol. 2 (No. 8513), pp. 943-46 (October 25, 1986).	8
		PLYMATE, ET AL., "Circadian Variation in Testosterone, Sex Hormone-Binding Globulin and Calculated Non-Sex Hormone-Binding Globulin Bound Testosterone in Healthy Young and Elderly Men," Journal of Andrology, Vol. 10 (No. 5), pp. 366-371 (September-October 1989).	
Say	90	CUNNINGHAM, ET AL., "Testosterone Replacement with Transdermal Therapeutic Systems - Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels," JAMA, Vol. 261 (No. 17), pp. 2525-2530 (May 5, 1989).	

Examiner Signature	Say	Date Considered	5/21/02

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. control number.

Substitute fo	or form 1449B/PTO			Complete if Known			
		DIC	CLOCUDE	Application Number	09/703.753		
INFU	RIVIATION	פוח	CLOSURE	Filing Date	November 1, 2000		
STAT	FMFNT R	ΥΔ	PPLICANT	First Named Inventor	Robert E. Dudley		
OIA.			I LIOAN	Group Art Unit	1617		
	(use as many sh	eets a	s necessary)	Examiner Name	S. Jiang		
Sheet	7	of	21	Attorney Docket Number	01736349		

			NON PATENT LITERATURE DOCUMENTS	
	Examiner C		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
59		91_	TENOVER, ET AL., "Age-Related Alterations in the Circadian Rhythms of Pulsatile Luteinizing Hormone and Testosterone Secretion in Healthy Men," Journal of Gerontology, Vol. 43 (No. 6), pp. M163-169 (November 1988).	
		92	CONWAY, ET AL., "Randomized Clinical Trial of Testosterone Replacement Therapy in Hypogonadal Men," International Journal Of Andrology, Vol. 11 (No. 4), pp. 247-264 (August 1988).	
	-	93	PLACE, ET AL., "Transdermal Delivery of Testosterone with Testoderm to Provide Normal Circadi Pattern of Testosterone," Annals New York Academy of Sciences, Vol. 618, pp. 441-449 (1991).	
		94	BHASIN, ET AL., "A Biodegradable Testosterone Microcapsule Formulation Provides Uniform Eugonadal Levels of Testosterone for 10-11 Weeks in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 1), pp. 75-83 (January 1992).	
		95	ARVER, ET AL., "Improvement of Sexual Function in Testosterone Deficient Men Treated for 1 Year with Permeation Enhanced Testosterone Transdermal System," Journal Of Urology, Vol. 155 (No. 5), pp. 1604-1608 (May 1996).	
· · · · ·		96	LIAO, "Androgen Action: Molecular Mechanism and Medical Application," J Formos Med. Assoc., Vol. 93 (No. 9), pp. 741-751 (September 1994).	0.600
		97_	CARLSTROM, ET AL., "Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function," International Journal Of Andrology (Vol. 13), pp. 67-73 (1990).	
		98	de LIGNIERES, ET AL., "Treatment of Male Hypogonadism by Topical Administration of Androgens," pp. 273-283 (1980).	3[
		99	DAVIDSON, ET AL., "Hormonal Changes and Sexual Function in Aging Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 57 (No. 1), pp. 71-77 (1983).	CH CE
		100	VERMEULEN, ET AL., "Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins," Maturitas, Vol. 7, pp. 281-287 (1985).	L.
5	a	101	MORRISON, "Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women," Psychopharmacology Bulletin, Vol. 33 (No. 2), pp. 293-296 (1997).	600/2900

Examiner Date Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449B/PTO **Application Number** 09/703.753 **INFORMATION DISCLOSURE** November 1, 2000 Filing Date STATEMENT BY APPLICANT First Named Inventor Robert E. Dudley Group Art Unit 1617 (use as many sheets as necessary) **Examiner Name** S. Jiang of Attorney Docket Number Sheet 01736349

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL' LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
99)	102	JAFFE, ET AL., "Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men", Horm. Res., Vol. 41, pp. 215-217 (1994).	
	103	MORLEY, ET AL., "Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy," J. Lab. Clin. Med., Vol. 135 (No. 5), pp. 370-378 (May 2000).	
	104	MARIN, ET AL., "Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues," European Journal of Medicine, Vol. 1 (No. 6), pp. 329-336 (October 1992)	A
	105	WANG, ET AL., "Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study," The Journal Of Endocrinology And Metabolism, Vol. 85 (No. 3), pp. 964-969 (March 2000).	9R ₁ (
	106	KUHN, ET AL., "Percutaneous Androgen Treatment for Male Hypogonadism. Compared Efficacy of Testosterone and Dihydrotestosterone: Study of 40 Observations," Endocrinologie, Vol. 14 (No. 11), pp 1031-1036 (1986) (English Translation).	2007.
	107	HANDELSMAN, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Pelle Man," Journal Of Clinical Endocrinology And Metabolism, Vol. 70 (No. 1), pp. 216-222 (1990).	
		STUENKEL, ET AL., "Sublingual Administration of Testosterone-Hydroxypropyl-b-Cyclodextrin Inclusion Complex Simulates Episodic Androgen Release in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 72 (No.5), pp. 1054-1059 (May 1991).	
		BHASIN, "Clinical Review 34 - Androgen Treatment of Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 6), pp. 1221-1225 (June 1992).	101F
		SALEHIAN, ET AL., "Pharmacokinetics, Bioefficacy, and Safety of Sublingual Testosterone Cyclodextrin in Hypogonadal Men: Comparison to Testosterone Enanthate - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 80 (No. 12), pp. 3567-3575 (1995).	
		MEIKLE, ET AL., "Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 5), pp. 1832-1840 (May 1996).	
599	/	WANG, ET AL., "Testosterone Replacement Therapy Improves Mood in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3578-3583 (1996).	

Examiner Signature	Say	Date Considered	5/21/02
*EXAMINER: Initial if reference	considered, whether or not citation is in conforma	ance with MPEP 609. Draw line th	nrough citation if not in conforman

and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	or form 1449B/PTO			Complete if Known		
INITOT	SRAATION I)IC	CLOCUDE	Application Number	09/703.753	
INLO	TIVIA HON I	פוע	CLOSURE	Filing Date	November 1, 2000	
STATI	EMENT BY	′ Δ	PPLICANT	First Named Inventor	Robert E. Dudlev	
	D :			Group Art Unit	1617	
	(use as many she	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	9	of	21	Attorney Docket Number	01736349	フ

			NON PATENT LITERATURE DOCUMENTS	·	
Exam Initial		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
29		113	WANG, ET AL., "Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3654-3662 (1996).		
	·	114	McCLELLAN, ET AL., "Transdermal Testosterone," Drugs, Vol. 55 (No. 2), pp. 253-258 (February 1998).	11	
		115	BHASIN, ET AL., "Therapeutic Perspective - Issues in Testosterone Replacement in Older Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 10), pp. 3435-3448 (1998).	CH CE	AΡ
		116	BEHRE, ET AL., "Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male Hypogonadism: Phase I Studies," European Journal Of Endocrinology, Vol. 140, pp. 414-419 (1999).	NTER	R 1 6
		117	BEHRE, ET AL., "Long-Term Substitution Therapy of Hypogonadal Men with Transscrotal Testosterone Over 7-10 Years," Clinical Endocrinology, Vol. 50, pp. 629-635 (1999).	1800/o	2002
-		118	PARKER, ET AL., "Experience with Transdermal Testosterone Replacement Therapy for Hypogonadal Men," Clinical Endocrinology, Vol. 50, pp. 57-62 (1999).	S	
-	,	119	SNYDER, ET AL., "Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age," The Journal Of Clinical Endocrinology And Metabolism, Vol.84 (No. 6), pp. 1966-1972 (1999).		
			WANG, ET AL., "Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 8), pp. 2749-2757 (August 1998).		150
		121	LEIFKE, ET AL., "Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Vertebral Body Area and Paraspinal Muscle Area in Hypogonadal Men," European Journal of Endocrinology, Vol. 138, pp. 51-58 (1998).		CENI
5			BEHRE, ET AL., "Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 82 (No. 8), pp. 2386-2390 (1997).		ECH CENTER 1600/2900
					B

Examiner	$\leq \wedge \gamma$	Date	8/2-1/0
Signature		Considered	0/2002

^{*}EXAMINER: Initial if reference considered, whether or not offation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO 09/703.753 Application Number INFORMATION DISCLOSURE Filing Date November 1, 2000 STATEMENT BY APPLICANT First Named Inventor Robert E. Dudley Group Art Unit 1617 (use as many sheets as necessary) S. Jiang **Examiner Name** Sheet of Attorney Docket Number 01736349

		NON PATENT LITERATURE DOCUMENTS		7
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
396	123	DAMASSA, ET AL., "Sex Hormone-Binding Globulin and Male Sexual Development," Neuroscience And Biobehavioral Reviews, Vol. 19 (No. 2), pp. 165-175 (1995).		
	124	MORLEY, ET AL., "Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men," Metabolism, Vol. 46 (No. 4), pp. 410-413 (April 1997).		
	125	CUNNINGHAM, ET AL., "Plasma Sex Hormone-Binding Globulin Levels Decrease During the Second Decade of Life Irrespective of Pubertal Status," Journal Of Clinical Endocrinology And Metabolism, Vol. 58 (No. 5), pp. 915-918 (1984).	IEC	
	126	LEWIS, ET AL., "Serum 5a-Dihydrotestosterone and Testosterone Changes with Age in Man," ACTA Endocrinologica, Vol. 82, pp. 444-448 (1976).	H CEN	
	127	HARDY, ET AL, "Endocrine Assessment of Impotence - Pitfalls of Measuring Serum Testosterone Without Sex-Hormone-Binding Globulin," Postgrad Medical Journal, Vol. 70, pp. 836-837 (1994).		
	128	DAVIDSON, ET AL., "Hormonal Replacement and Sexuality in Men," Clinics In Endocrinology And Metabolism, Vol. 11 (No. 3), pp. 599-623 (November 1982).	1600/290	
	129	MANTZOROS, ET AL., "Contribution of Dihydrotestosterone to Male Sexual Behavior," British Medical Journal, Vol. 310, pp 1289-1291 (May 20, 1995).	3	
	130	MOORADIAN, ET AL., "Biological Actions of Androgens," Endocrine Reviews, Vol. 8 (No. 1), pp 1-28 (1987).	1	
	131	CUNNINGHAM, ET AL., "Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men," Journal Of Clinical Endocrinology and Metabolism, Vol. 70 (No. 3), pp. 792-797 (1990).)	1 7
	132	SKAKKEBAEK, ET AL., "Androgen Replacement with Oral Testosterone Undecanoate in Hypogonadal Men: A Double Blind Controlled Study," Clinical Endocrinology, Vol. 14, pp. 49-61 (1981).		
10)			
ブル	133	de LIGNIERES, "Transdermal Dihydrotestosterone Treatment of Andropause," Annals Of Medicine, Vol. 25, pp. 235-241 (1993).		

Examiner Signature Date Considered 5/20/52

RECEIVED

RECEIVED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	or form 1449B/PTO			Co	mplete if Known	
		NC	CLOCUDE	Application Number	09/703.753	
INFOR	KIVIATION L	JIS	CLOSURE	Filing Date	November 1, 2000	
STAT	EMENT BY	Δ	PPLICANT	First Named Inventor	Robert E. Dudlev	
		•	LIOAIT	Group Art Unit	1617	
	(use as many shee	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	11	of	21	Attorney Docket Number	01736349	

			NON PATENT LITERATURE DOCUMENTS		
Exar Initia	miner ils*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
9		134	CHEMANA, ET AL., "Percutaneous Absorption of 5a-dihydrotestosterone in Man II. Percutaneous Administration of 5a-dihydrotestosterone in Hypogonadal Men with Idiopathic Haemochromatosis: Clinical, Metabolic and Hormonal Effectiveness," International Journal Of Andrology, Vol. 5, pp. 595-606 (1982).		
		135	McCLURE, ET AL., "Hypogonadal Impotence Treated by Transdermal Testosterone," Urology, Vol. XXXVII (No. 3), pp. 224-228 (March 1991).		
GOOREN, "Androgen Levels and Sex Functions in Testosterone-Treated Hy 136 Men," Archives Of Sexual Behavior, Vol. 16 (No. 6), pp. 463-473 (1987).					
		137	TSITOURAS, "Effects of Age on Testicular Function," Endocrinology And Metabolism Clinics, Vol. 16 (No. 4), pp.1045-1059 (December 1987).	1.	
		138	ANDERSON, ET AL., "The Effects of Exogenous Testosterone on Sexuality and Mood of Normal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 75 (No. 6), pp.1503-1507 (1993)	. 00	
		139	KNUSSMANN, ET AL., "Relations Between Sex Hormone Levels and Sexual Behavior in Men," Archives Of Sexual Behavior, Vol. 15 (No.5), pp. 429-5 (1986).		
		140	BANCROFT, "Endocrinology of Sexual Function," Clinics In Obstetrics And Gynecology, Vol. 7 (No. 2), pp. 253-281 (August 1980).		
		141	BAGATELL, ET AL., "Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 78 (No. 3), pp. 711-716 (1994).		
		142	WEINBAUER, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate and Dihyrotestosterone Enanthate in Non-Human Primates," ACTA Endocrinologica (COPENH), Vol. 122 (No. 4), pp. 432-442 (1990).	ΑP	
			"Sexual Dysfunction in the Male - Sexual Arousal Disorder," The Merck Manual, Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992).	R 1 6 200	
_	8	_	JOCKENHOVEL, ET AL., "Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men," Clinical Endocrinology, Vol. 45, pp. 61-71 (1996).	٦٥	

Examiner		Date 12.15
Signature	<i>Y</i> 7	Considered 3/ 2/02

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute fo	r form 1449B/PTO			Complete if Known			
INFORMATION DISCLOSURE		Application Number	09/703.753				
INFOR	CIVIA HON L	ノに	CLUSURE	Filing Date	November 1, 2000		
STATI	FMFNT RY	' Δ	PPLICANT	First Named Inventor	Robert E. Dudley		
• • • • • • • • • • • • • • • • • • • •			II LIOAIII	Group Art Unit	1617		
	(use as many she	ets a	as necessary)		S. Jiang		
Sheet	12	of	21	Attorney Docket Number	01736349		

			NON PATENT LITERATURE DOCUMENTS		
Examiner Cité item (Cité No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
2	aS	145	BEHRE, ET AL., "Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester," Journal Of Endocrinology And Metabolism," Vol. 75 (No. 5), pp. 1204-1210 (1992).		
SCHURMEYER, ET AL., "Comparative Pharmacokinetics of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men," International Journal of Andrology, Vol. 7, pp. 181-187 (1984).					
		147	MAZER, ET AL., "Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men," Journal of Controlled Release, Vol. 19, pp. 347-361 (1992).	∂ .0.0	
	-	148	COFRANCESCO, Jr., ET AL., "Transdermal Testosterone Delivery System The Endocrinologist, Vol. 6 (No. 3), pp. 207-213 (1996).	6	
		149	BROCKS, ET AL., "Pharmacokinetics of Testosterone in Hypogonadal Men After Transdemal. Delivery: Influence of Dose," Journal of Clinical Pharmacology, Vol. 36, pp. 732-739 (19).	2002	
		150	ARVER, ET AL., "Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men," Clinical Endocrinology, Vol. 47, pp. 727-737 (1997).		
		151	MEIKLE, ET AL., "Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 43, pp. 449-457 (1996 Wiley-Liss, Inc.).		
		152	BALS-PRATSCH, ET AL., "Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year," ACTA Endocrinologica (COPENH), Vol. 118, pp. 7-13 (1988)		
		153	CAREY, ET AL., "Transdermal Testosterone Treatment of Hypogonadal Memily The Journal of Urology, Vol. 140, pp. 76-79, (July 1988).		
		1 ∕54	CUNNINGHAM, ET AL., "Testosterone Transdermal Delivery System," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 42, pp. 437-447 (1996 Wiley-Liss, Inc).	APR 1 6	
S		155	Product Information - Testoderm TTS, Physicians' Desk Reference, Alza pp 517-520.	2002	

Examiner Signature Date Considered 5/21/07			
	 SAX	Considered	5/21/02

RECEIVED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031

01736349

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 09/703.753

Filing Date November 1, 2000

First Named Inventor Robert E. Dudley

Group Art Unit 1617

Examiner Name S. Jiang

Attorney Docket Number

13

Sheet

Examiner

Signature

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials* number(s), publisher, city and/or country where published YU, ET AL., "Testosterone Pharmacokinetics after Application of an Investigational Transdermal 156 System in Hypogonadal Men," Journal of Clinical Pharmacology, Vol. 37, pp. 1139-1145 (1997). YU, ET AL., "Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application." 157 Journal of Clinical Pharmacology, Vol. 37, pp. 1129-1138 (1997). WALTERS, "Penetration Enhancers and Their Use in Transdermal Therapeut 158 Systems," pp. 202-227 (1990). GENNARO, "Remington: The Science and Practice of Pharmacy, 20th Edition 159 Chapter 44, pp. 842-843 (2000). JARKANDER-ROLFF, ET AL., "Transdermal Application of A Testosterone 160 Gel - A Pharmacokinetic Study." TIRASSA, ET AL., "High-Dose Anabolic Androgenic Steroids Modulate Concentrations of N Growth Factor and Expression of its Low Affinity Receptor (p75-NGFr) in Male Rat Brain," Journal of Neuroscience Research, Vol. 47 (No. 2), pp. 198-207 (January 15, 1997) VELDHUIS, ET AL., "Muting of Androgen Negative Feedback Unveils Impoverished Gonadotropin-Releasing Hormone/Luteinizing Hormone Secretory Reactivity in Healthy Older Men," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No. 2), pp. 529-535. (2001) MILLER, ET AL., "Androgen Deficiency in Women with Hypopituitarism," The 163 Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No.2), pp. 561-567 (2001) KAO, ET AL., "Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: in vitro Studies with Mouse Skin in Organ Culture," Journal of Pharmacology and Experimental Therapeutics, 164 Vol. 241 (No. 2), pp. 482-487 (May 1987). FINDLAY, ET AL., "Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone," Journal Of Clinical Endocrinology 165 And Metabolism, Vol. 68 (No. 2), pp. 369-373 (February 1989). ERNESTI, ET AL., "Absorption and Metabolism of Topically Applied Testosterone in an Organotypic Skin Culture," Skin Pharmacology, Vol. 5 (N 166|3), pp. 146-153 (1992).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

20/00E	(10-01)	
OMB 0	651-0031	•
OF COM	MERCE	_

Substitute fo	or form 1449B/PTO			Complete if Known				
INFORMATION DISCLOSURE E		Application Number	09/703.753					
INFORMATION DISCLOSURE				Filing Date	November 1, 2000			
STATEMENT BY APPLICANT		First Named Inventor	Robert E. Dudley					
• . ,		• • •	i i Lioziii	Group Art Unit	1617			
	(use as many sh	eets a	s_necessary)	Examiner Name	S. Jiang			
Sheet	14	of	21	Attorney Docket Number	01736349			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
90	167	CHOI, ET AL., "Transdermal Dihydrotestosterone Therapy and its Effects on Patients with Microphallus," Journal Of Urology, Vol. 150 (No. 2) (Part 2), pp. 657-660 (August 1993).	h
	168	Testosterone, Chapters 1, 6-16 (1999).	
	169	TSAI, ET AL., "Metabolic Approaches to Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors," Journal of Pharmaceutical Sciences, Vol. 85 (No. 6), pp. 643-648 (June 1996).	
	170	MEIKLE, ET AL., "Familial Effects on Plasma Sex-Steroid Content in Man: Testosterone, Estradad and Sex-Hormone-Binding Globulin," Metabolism, Vol. 31 (No. 1), pp. 6-9 (January 1982).	
	171	SHANBHAG, ET AL., "The Temperature Dependence of the Binding of 5 Alpha-Dihydrotestosterone, Testosterone and Estradiol to the Sex Hormone Globulin (SHBG) of Human Plasma," J. Steroid Biochem. Vol. 24 (No. 2), pp. 549-555 (February 1986).	
	172	BELGOROSKY, ET AL., "Changes in Serum Sex Hormone-Binding Globulin and in Serum Non-Sex Hormone-Binding Globulin-Bound Testosterone During Prepuberty in Boys," J. Steroig Biochem., Vol. 27 (Nos. 1-3), pp. 291-295 (1987).	1
	173	KORENMAN, ET AL., "Androgen Therapy of Hypogonadal Men with Transscrotal Testoster Systems," American Journal Of Medicine, Vol. 83 (No. 3), pp. 471-478 (September 1987).	
	- 1	MITCHELL, ET AL., "Age Related Changes in the Pituitary-Testicular Axis in Normal Men; Lower Serum Testosterone Results from Decreased Bioactive LH Drive," Clinical Endocrinology (OXF), Vol. 42 (No. 5), pp. 501-507 (May 1995).	
	175	NANKIN, ET AL., "Decreased Bioavailable Testosterone In Aging Normal and Impotent Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 6), pp. 1418-1420 (December 1986).	
		TENOVER, ET AL., "The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clomiphene Citrate," Journal Of Clinical Endocrinology And Metabolism, Vol. 65 (No. 6)	ДÞ
99		WINTERS, ET AL., "The Gonadotropin-Suppressive Activity of Androgen is Increased in Elderly Men," Metabolism, Vol. 33 (No. 11), pp. 1052-1059 (November 1984).	R 1 6 2002

Examiner Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449B/PTO **Application Number** 09/703.753 INFORMATION DISCLOSURE November 1, 2000 Filing Date STATEMENT BY APPLICANT Robert E. Dudley First Named Inventor 1617 Group Art Unit (use as many sheets as necessary) Examiner Name <u>S. Jianq</u> :15 21 -Sheet Attorney Docket Number 01736349

	NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Citer) N/6.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²						
Say) 178	MEIKLE, ET AL., "Enhanced Transdermal Delivery of Testosterone Across Nonscrotal Skin Produces Physiological Concentrations of Testosterone and Its Metabolites in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 3), pp. 623-628 (March 1992).							
WINTERS, ET AL., "Serum LH Concentrations in Hypogonadal Men During Transdermal Testosterone Replacement Through Scrotal Skin: Further Evidence That Ageing Enhances Testosterone Negative Feedback. 179 The Testoderm Study Group," Clinical Endocrinology (OXF), Vol. 47 (No. 3), pp. 317-322 (September 1997).									
	180	BOYLE, ET AL., "Serum Testosterone Measurements," American Journal Of Clinical Pathology, Vol. 81 (No. 6), pp. 754-761 (June 1984).	HOJ.						
	181	HOLOWNIA, ET AL., "A Clinical Evaluation of A Direct Radioimmunoassay of Testosterone," Clinical Chimica Acta, Vol. 214 (No. 1), pp. 31-43 (January 31, 1993).	CENTER						
	182	BELGOROSKY, ET AL., "Progressive Decrease in Serum Sex Hormone-Binding Globulin from Infancy to Late Prepuberty in Boys," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 2), pp. 510-512 (August 1986).							
	183	VALERO-POLITI, ET AL., "Daily Rhythmic and Non-Rhythmic Variations of Follitropin, Lutropin, Testosterone, and Sex-Hormone-Binding Globulin in Men," Eur. J. Clin. Chem. Clin. Biochem., Vol. 34 (No. 6), pp. 455-462 (June 1996).	1600 2900						
	184	VALERO-POLITI, ET AL., "Annual Rhythmic Variations of Follitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men," Clinica Chimica Acta, Vol. 271 (No. 1), pp. 57-71 (March 9, 1998).							
	185	LONGCOPE, ET AL., "Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 71 (No. 6), pp. 1442-1446 (December 1990).							
	186	BELGOROSKY, ET AL., "Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones," J. Steroid Biochem., Vol. 18 (No. 6), pp. 783-787 (Line 1983).							
	187	LEWIS, ET AL., "Proceedings: Age-Related Changes in Serum 5aplha-dihydrotestosterone and Testosterone in Normal Men," Journal Of Endocrinology, Vol. 67 (No. 2), pg. 15P (November 1975).	2 9 I 84V						
Sol	188	PIRKE, ET AL., "Age Related Changes and Interrelationships Between Plasma Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males," ACTA Endocrinologica (COPENH), Vol. 74 (No. 4), pp. 792-800 (December 1973).	zuuz						

Examiner Date Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 6651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Attorney Docket Number

Substitute for form 1449B/PTO

Sheet

Examiner Signature

16

of

Complete if Known **Application Number** 09/703.753 INFORMATION DISCLOSURE November 1, 2000 Filing Date Robert E. Dudley STATEMENT BY APPLICANT **First Named Inventor** Group Art Unit S. Jiang (use as many sheets as necessary) **Examiner Name**

01736349

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
And	189	MASTERS, ET AL., "Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol," Clinical Chemistry, Vol. 35 (No. 6), pp. 979-984 (June 1989).	HOH
	190	WANG, ET AL., "Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 53 (No. 5), pp. 1021-1024 (November 1981).	CENTER
	191	ZMUDA, ET AL., "Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men," Metabolism, Vol. 45 (No. 8), pp. 935-939 (August 1996).	-R 160
	192	GAIDANO, ET AL., "Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty," Clinical Chimica Acta, Vol. 100 (No. 2), pp. 91-97 (January 15, 1980).	1600/2900
	193	Definition of Isopropyl Myristate (5103), The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals, Eleventh Edition, p. 821 (1989).	
	194	GENNARO, ET AL., Remington's Pharmaceutical Sciences, Eighteenth Edition, pp. 1305, 1314-1315 (1990).	1ECH
	195	LANGTRY, ET AL., "Sildenafil - A Review of its Use in Erectile Dysfunction," Drugs, Vol. 57 (No. 6), pp. 967-989 (1999).	CENTER
	196	MORELAND, ET AL., "Sildenafil, A Novel Inhibitor of Phosphodiesterase Type 5 In Human Corpus Cavernosum Smooth Muscle Cells," Life Sciences, Vol. 62 (No. 20) pp. PL309-318 (1998).	R 160
	197	MORELAND, ET AL., "Sildenafil, A Novel Inhibitor of Phosphodiesterase Type 5 In Human Corpus Cavernosum Smooth Muscle Cells," Life Sciences, Vol. 62 (No. 20) pp. PL309-318 (1998). FAHRNER, ET AL., "Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG)," International Journal Of Sports Medicine, Vol. 19 (No. 1), pp. 12-15 (January 1998). [Abstract]	0/2900
		BARTSCH, "Interrelationships Between Sex Hormone-Binding Globulin and Testosterone, 5 alpha-Dihydrotestosterone and Oestradiol-17 beta in Blood of Normal Men," Maturitas, Vol. 2 (No. 2), pp. 109-118 (July 1980). [Abstract]	
	199	WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," Clinical Endocrinology, Vol. 54, pp. 1-13 (2001).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO 09/703.753 Application Number INFORMATION DISCLOSURE November 1, 2000 Filing Date STATEMENT BY APPLICANT **First Named Inventor** Robert E. Dudley Group Art Unit 1617 (use as many sheets as necessary) **Examiner Name** S. Jiang 17 Attorney Docket Number Sheet of 01736349

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
697	200	GOOREN, "A Ten-Year Safety Study of the Oral Androgen Testosterone Undecanoate," J. Androl., Vol. 15 (No. 3), pp. 212-215 (May-June 1994). [Abstract]	
	201	MAZER, "New Clinical Applications of Transdermal Testosterone Delivery in Men and Women," J. Controlled Release, Vol. 65 (No. 1-2), pp. 303-315 (March 1, 2000). [Abstract]	
40	202	ITOH, ET AL., "The Assessment of Bioavailable Androgen Levels from the Serum Free Testosteron Level, "Nippon Naibunpi Gakkai Zasshi, Vol. 67 (No. 1), pp. 23-32 (January 20, 1991). [Abstract]	150
	20 3	Male Hormone Patch Approved, Nupharm, http://www.nupharm.com/malehorm.htm:	CEN
	204	"SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available," International Association of Physicians in AIDS Care, http://www.iapac.org/clinmgucompnews/sb061297:html*(June-12,-1997).	[ER 16
	205	"Impotence Treatments," Impotence World Association, http://www.impotenceworld.org/treatment.htm (2000).	LEH 18001 YEL
	206	"Andro Gel," Netrition, http://www.netrition.com/andro_gel_page.html (1997-1998).	
	207	"Cellegy Pharmaceuticals Market Opportunities," CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market-html-(1997)	
		"Prospectus - Cellegy Pharmaceuticals, Inc.," OPPENHEIMER & CO., pp. 1-421-28 (1997).	APR
		TER 16	9 j
	209	The Testosterone Source, http://www.testosteronesource.com-(-1998).	2002
		BONNEY, "Hormone Replacement Therapy for Men," American Clinical Laboratory, http://iscpubs.com/pubs/acl/acl/197-html	
		(November/December1997).	

Examiner	: 590	Date	7	1	1/0
Signature		Considered	<u> </u>	/ - /	
	· · · · · · · · · · · · · · · · · · ·			,	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

			PTC)/SB/08B	(10-01
\pproved	for use	e through	10/31/2002.		

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 1449B/PTO			Complete if Known		
Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 18 of 21	CLOCUDE	Application Number	09/703.753			
INFOR	KIVIATION	כוע	CLOSURE	Filing Date	November 1, 2000	
STAT	EMENT BY	′Δ	PPI ICANT	First Named Inventor	Robert E. Dudlev	
• • • • • • • • • • • • • • • • • • •		, ,		Group Art Unit	1617	
	(use as many she	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	18	of	21	Attorney Docket Number	01736349	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	211	Andropausal, Los Gatos Longevity Institute, http://www.antiaging.com/andropause.html (1998).	
	212	TestoCreme - A Natural Transdermal Testosterone Replacement Therapy, www.testocreme.com.	APR
69N	213	WANG, ET AL., "Pharmacokinetics Of Transdermal Testosterone Gel in Hypogottal damen," ENDO '98 SUBMISSION PROGRAM, 1998N ABSTRACT FORM.	6 2
	214	SWERDLOFF, ETAL., "Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men," 2347 Male Reproductive Poster Session, Board 578 (June 22, 2000).	002
	215	WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," 2348 Male Reproductive Poster Session, Board 579 (June 22, 2000).	
	216	WANG, ET AL, "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," Basic Science: Reproduction-Gonadal Control (Male), Male Reproduction Oral Session, No. 1360 (June 24, 2000).	
	217	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www. INCIID.com (August 19, 1998).	
SA	218	RIGGS, "Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel," Unimed News Release, pp. 1-2 (March 31, 1997).	CHO
	219	Androgel 1% (testosterone gel) CHL; www-Androgel.com, pp. 1-2.	NIER
	/	VERGEL, "Anabolic Steroids: A Practical Guide," CRIA Update, Vol. 7 (No. 3)	1600/290
// · · ·		(Summer 1998). MOONEY, "Frequencey of Administration - Testosterone & Nandrolone," Vol. 1	
		(No. 4), www:medibolics:com-(Downloaded-10/8/98).	

Examiner Signature	547	Date Considered 5/2 1/02

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO	Complete if Known		
	Application Number	09/703.753	
NFORMATION DISCLOSURE	Filing Date	November 1, 2000	=
STATEMENT BY APPLICANT	First Named Inventor	Robert E. Dudley	₫
SIAILMENT BI AITEIOAN	Group Art Unit	1617	
(use as many sheets as necessary)	Examiner Name	S. Jiang	
Sheet 19 of 21	Attorney Docket Number	01736349	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ	かっかっ
	222	Anabolic Steroids, Project Inform, Anabolic Steroids Quick Sheet (December 1997).	_	_
	223	"Anabolic Steroid Boosts Weight," GMHC Treatment Issues, Vol. 10, No. 9 (September 1996).		
Mana Jeres & S	224	Anabolic Steroids, Project-Inform Hotline Handout, www.projinf.org. (Downloaded 10/8/98).	CHC	_ } }
	225	Anabolic Steroids - A Simple Facts Sheet From The Network, www.network/simple/steroids (Downloaded 10/27/98).	NILK	; 1 1 2
New york the complete	226	USP Drug Information - Anabolic Steroids (Systemic), MayoClinic, www.mayohealth.org (Downloaded 10/8/98).	1000/2	2000
	227	MOONEY, "Anabolic Steroids For AIDS Therapy: Differences Between Analogs," No. 1, www.digiweb.com. (July 1998).	S.	3
	228	Testocreme - No Shots, No Pills, No Patches, www.testocreme.com (Downloaded 7/10/00).	tako Misika	hy. g
	229	"ENDO 99: Testosterone Patch Effective For Diminished Sexual Function in Surgically Menopausal Women," www.pslgroup.com (June 15, 1999).		
الد التناويس والنط		"Data Supports Safety of Estratest For Men," Doctor's Guide, www.pslgroup.ed (March 9, 1998).	n D	-
		"Testosterone's Role in the Female Sex Drive," USA Today News, www.usatoday.com (April 8, 1996).	VENTED 18	
		"Alternative to Viagra For Women?," www.mdhealthline.com (Downloaded	70/2007	_
	232	8/7/00).	\perp	

Date Examiner Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	r form 1449B/PTO			Complete if Known		
	-	NIC	CLOCUDE	Application Number	09/703.753	
INFUR	KIVIATION L	JIO	CLOSURE	Filing Date	November 1, 2000	
STATE	MENT RY	' Δ	PPLICANT	First Named Inventor	Robert E. Dudley	
	-::::::: D :	_		Group Art Unit	1617	
	(use as many she	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	- 20	of	21	Attorney Docket Number	01736349	

			1
		NON PATENT LITERATURE DOCUMENTS	4
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
\delta	7	<u>£</u>	1
41	222	L	×
/	233	"Never Too Buff," Time Europe, www.time.com, Vol. 155 (No. 16) (April 24, 2000).	E 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
	ĺ	i 🔝	1
	234	Gefael, Graeme's Testosterone-Page, www:voyager:co:nz (5/12/00).	. 0
		9	ק≃
	225	B. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	2002
-	233	Estrogel, www:netdoktor:dk/medicin/Fakta/Estrogel-(Downloaded 6/26/01).	4
		La Sexualite, L'Androgel, Le Gel Miracle,	
	236	www.aci-multimedia:net/feminin/androgel-(Downloaded-5/9/01):	ı
			₹
		Stehli, et al., Info, Info Androgel,	잭
	23 /	www.mageos.ifrance.com/nade38/androgel (Downloaded-5/9/01).	
		CHERRIER, ET AL., "T-Gel Study: Cognitive Effects of Exogenous	ተ
	238	Testosterone Manipulation in Hypogonadal Men" (6/7/99).	4
	230	"Bentley Pharmaceuticals Annouces Research and Licensing Agreements For Intranasal Pain	#3
]	"Bentley Pharmaceuticals Annouces Research and Licensing Agreements For Intranasal Pain Management-and-Fopical-Hormone-Replacement. Therapy," www.bentleypharm.com (downloaded)	
	239	11/17/01).	
			1
		"Testosterone Gel May Help Men with Low Sex Drive," WRAL ONLINE,	
e i kamendar	240	http://www.wral-tv.com/features/healthteam/1997/0814-tgel/(August 14, 1997).	_
-0784	المديعتان	"Testocreme Transdermal Testosterone Is New," Preventive Medicine Clinic Of	
Carl San Francisco	241	Monterey, http://www.wellnessmd.com/testo.html.	
			┨┲
			エスス
0	- 10am	"SEPA Testosterone Transdermal Gel Receives-Application-by-FDA," Doctor's	1
	242	Guide Global Edition, http://pslgroup.com/dg/123aa.htm (January 15, 1997).	-
	242		
		Press Release - 10/21/99 MacroChem Awarded U.S. Patent Covering	7007
	<u> </u>	Transdermal-Hormone-Replacement-Incorporating-Proprietary_SEPA Technology	'`
		and Hormonally Active Drugs Such as Testosterone, Estradiol and Progesterone,	
	243	http://www.mchm.com/press/pr24.asp (October 21, 1999).	┛
			_
Examine	rl	CACK Date Could be	1

Considered Signature

CEIVEDRECEIVE

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 1449B/PTO			Complete if Known		
INEOE	I IAOITABA)IC	CLOSURE	Application Number	09/703.753	
INFOR	KIVIATION L	JIO	CLOSURE	Filing Date	November 1, 2000	
STATI	EMENT BY	À	PPLICANT	First Named Inventor	Robert E. Dudley	
• ,,		•	2.0/(//	Group Art Unit	1617	
	(use as many shee	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	21	of	21	Attorney Docket Number	01736615	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T² D
	244	AndrosteDERM, http://www.gethuge.net/androderm1.htm.	PR 1
	245	MANOS, "FDA Approves Gel to Treat Low Testosterone Levels," www.testocreme.com (Downloaded 5/09/01).	2002
******	246	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www.INCIID.com (August 19, 1998).	
591	247	LACAYO, "Are You Man Enough?," Time Europe, www.Time.com, Vol. 155, No. 16 (April 24, 2000).	
·	248	"MacroChem Accelerates Development of Top For Impotence," www.pslgroup.com (April 10, 1997).	-
59) 1	249	BRADLEY, "Potential Expanded Indications for Androgen Treatment," The Endocrine Society, No. 166 (ENDO 2000).	HPK
	250	WANG, ET AL., "New Androgen Formulations," The Endocrine Society, No. 20167 (ENDO 2000).	0 كرر
	251	WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," The Endocrine Society, No. 1360 (END) 2000).	70
	252	WITTERT, ET AL., "Androgen Deficiency in Aging Men," The Endocrine Society, No. 1626 (ENDO 2000).	
9	253	BRILL, ET AL., "Single and Joint Impact of One-Month of Transdermal Testosterone (T) and/or Recombinant Human Growth Hormone (rhGH) Supplementation on Body Composition, Strength, Balance, Function and Muscle IGF-I and Androgen Gene Expression in Healthy Older Men: A Prospective Randomized Double-Blind Crossover," The Endocrine Society, No. 1647 (ENDO 2006)	
		600/29	/
Examine Signature		Date S/21/07	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.